BrightEdge is assembling a portfolio of companies to attack cancer from every angle.
Making early-stage cancer easier to find, starting with lung cancer
Developing the first and only test for early cancer detection based on analysis of single extracellular vesicles present in the blood at high-abundance.
Health engagement platform to reach complex populations, starting with smoking cessation
Developing a breakthrough health engagement and prevention platform for the most complex, costly populations, and hardest to help low-income - starting with smoking cessation
Developing technologies for early viral cancer detection
Improving outcomes for the millions of people at risk of developing viral cancers through novel molecular diagnostics that enable earlier cancer detection.
Pioneering small molecule inhibition of p300/CBP to treat cancer
A research driven and patient-centric clinical stage, private biotechnology company pioneering small molecule inhibition of the twin proteins, p300/CBP
Unlocking the gut microbiome for all
Developing precision immunotherapies utilizing synthetic biology and companion diagnostics for unmet needs and more equitable treatment outcomes
Making data-driven medicine the new standard of cancer care
AI-powered diagnostic tools for cancer screening and biomarkers that can predict and guide patient responses to cancer therapy
Harnessing sonodynamic therapy to fight solid tumors
Developing a sonodynamic therapy platform targeting solid body tumors, starting with glioblastoma
Leveraging exoneural biology to fight disease
The first company to build a platform to develop drugs in the new field of exoneural biology, translating the language of the peripheral nervous system to produce therapeutic breakthroughs and improve human health
Financial navigation platform removing barriers to care for patients
Harnessing technology to reduce financial hardships for patients and improve the financial performance of healthcare providers
Unlocking human immunology via novel single cell analyses
A first-in-class NK and T cell modulator targeting CD161, is being developed for the treatment of solid tumors and hematological malignancies. The company's programs are derived from their platform, a cross-functional, highly integrated, single cell genomics approach that enables rapid target identification and validation in parallel with antibody discovery and engineering.
Fighting cancer with differentiation therapy
Auron seeks to reprogram cells to elicit tumor cell maturation and reprogram cancer tissue to a more normal pehnotype
A novel approach to CAR T therapy
Developing novel cell engineering for in vivo CAR T
Immune activator intended to eliminate solid tumors
Developing immunotherapies designed to recognize and destroy tumor cells
Early detection via liquid biopsy
More accurately detecting cancer at earlier stages and define the tumor type to help oncologists select the best available treatment
Delivering next-gen T cell therapies
Developing diversified portfolio of novel treatments that exhibit best-in-class control over T cell activation and direction in the body. The company is focused on treating cancer, their first three targets are prostate, myeloma and ovarian.
Patient engagement & care management
A healthcare IT platform that allows for patients and their families to submit patient reported outcomes data to their oncology center in real time through the Company’s bidirectional interface with the oncology center’s EHR. Navigating Cancer’s proprietary predictive algorithm, allows for patients to be triaged so that interventions can occur when needed and the Company also distributes the right educational content to patients that has proven to improve compliance and adherence rates, and patient outcomes.
Precision medicine for melanoma
Develops and commercializes diagnostic and prognostic tests for dermatologic cancers. The tests provide clinically actionable, tumor-specific genomic information to enable more accurate treatment plan decisions.